Cyflwyniad a Throsoddview
This book provides an in-depth exploration of Prostaglandin E1 (PGE1), a substance that has been clinically available for an extended period but whose effectiveness in peripheral arterial occlusive disease has only recently been confirmed through controlled studies. The favorable outcomes observed in patients with critical limb ischemia and intermittent claudication have significantly spurred research into its clinical pharmacology.
The text highlights exciting new discoveries, including PGE1's anti-thrombotic, endothelium-stabilizing, and leukocyte-stabilizing properties, as well as its effects on lipid metabolism. These attributes, alongside its established anti-aggregating and vasodilator effects, contribute to its overall clinical efficacy. Furthermore, the book presents new data on PGE1 metabolism, particularly the identification of 13,14-dihydro-PGE1, a biologically active metabolite isolated in humans after PGE1 administration. The pharmacodynamic profile of 13,14-dihydro-PGE1 closely mirrors that of PGE1, offering insights into PGE1's efficacy despite its rapid metabolization when administered intravenously.
The cover features the title 'Prostaglandin E1' prominently, along with the editors' names (C. Diehm, H. Sinzinger, W. Rogatti) and the subtitle 'New Aspects on Pharmacology, Metabolism and Clinical Efficacy'. The Springer-Verlag logo is visible at the bottom.
Key Research Areas
The volume delves into several critical aspects of PGE1, including:
- Pharmacology of Prostaglandin E1
- Metabolism of PGE1, including the discovery of 13,14-dihydro-PGE1
- Clinical efficacy in peripheral arterial occlusive disease
- Anti-thrombotic properties
- Endothelium-stabilizing effects
- Leukocyte-stabilizing properties
- Impact on lipid metabolism
- Vasodilator and anti-aggregating effects
Intended Audience and Usage
This book is an essential resource for researchers, clinicians, pharmacologists, and students in the fields of cardiovascular medicine, internal medicine, and pathology. It serves as a comprehensive reference for understanding the latest advancements in PGE1 research and its therapeutic applications. Readers can utilize this text for in-depth study, clinical reference, and staying current with pharmacological developments.
Manylebau Llyfr
| Priodoledd | Manylyn |
|---|---|
| Cyhoeddwr | Springer |
| Dyddiad Cyhoeddi | Ionawr 20, 1992 |
| Argraffiad | 1af |
| Iaith | Saesneg |
| Hyd Argraffu | 128 tudalen |
| ISBN-10 | 3540545247 |
| ISBN-13 | 978-3540545248 |
| Pwysau Eitem | 6.9 owns |
| Dimensiynau | 6.1 x 0.31 x 9.25 modfedd |
Gwybodaeth a Chymorth i Gyhoeddwyr
This publication is brought to you by Springer, a leading global scientific, technical, and medical portfolio, providing researchers in academia, scientific institutions and corporate R&D departments with quality content through innovative information products and services.
For inquiries regarding the content, errata, or academic use of this publication, please refer to the official Springer website or contact their customer support channels directly. Specific support details are typically available on the publisher's official platforms.